Latest MedImmune Stories
RMB 60 Million Free Grant for Construction of Dedicated Production Facility BEIJING, April 24, 2014 /PRNewswire/ -- Sinovac Biotech Ltd.
ROCKVILLE, Md., April 8, 2014 /PRNewswire/ -- Biologics development and manufacturing services provider Omnia Biologics, Inc.
NES ZIONA, Israel, April 2, 2014 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd (TASE: BNDX), developer of a universal flu vaccine, announced today that its Board of Directors has approved
-- Conference Call Today, March 31, 2014, at 10:00 a.m. (EDT) -- ROCKVILLE, Md., March 31, 2014 /PRNewswire/ -- Synthetic Biologics, Inc.
LONDON and BOSTON, March 26, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company
HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate
DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jnwqq6/h1n1_vaccines) has announced the addition of the "H1N1
AVP-825 uses novel Breath Powered(TM) drug delivery to treat migraine YARDLEY, Pa., Jan.
SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced
-- Joseph Sliman, M.D., M.P.H., Joins Team as Senior Vice President, Clinical & Regulatory Affairs -- ROCKVILLE, Md., Jan. 27, 2014 /PRNewswire/ -- Synthetic Biologics, Inc.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.